Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199901 | 1.00 | MALT1 (0.49) | MALT1KMT2AELANEHRH3NTRK1 | |
| SCHEMBL2198937 | 0.95 | KMT2A (0.44) | MALT1KMT2ACCR3PTGS2MAPT | |
| SCHEMBL2198942 | 0.95 | KMT2A (0.44) | MALT1KMT2ACCR3PTGS2MAPT | |
| SCHEMBL2202091 | 0.91 | MALT1 (0.40) | MALT1KMT2ACCR3 | |
| SCHEMBL2202093 | 0.91 | MALT1 (0.40) | MALT1KMT2ACCR3 | |
| SCHEMBL2200676 | 0.90 | MALT1 (0.40) | MALT1KMT2ACCR3MAPT | |
| SCHEMBL2201732 | 0.90 | MALT1 (0.40) | MALT1KMT2ACCR3MAPT | |
| SCHEMBL2200677 | 0.90 | MALT1 (0.40) | MALT1KMT2ACCR3MAPT | |
| SCHEMBL2201736 | 0.90 | MALT1 (0.40) | MALT1KMT2ACCR3MAPT | |
| SCHEMBL2200679 | 0.90 | MALT1 (0.40) | MALT1KMT2ACCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | MALT1 3122/4885KMT2A 4057/4885ELANE 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.